Cargando…

Structure–Activity Relationship Studies on Novel Antiviral Agents for Norovirus Infections

Human norovirus is the leading cause of acute gastroenteritis worldwide, affecting every year 685 million people. Norovirus outbreaks are associated with very significant economic losses, with an estimated societal cost of 60 billion USD per year. Despite this, no therapeutic options or vaccines are...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferla, Salvatore, Varricchio, Carmine, Knight, William, Ho, Pui Kei, Saporito, Fabiana, Tropea, Beatrice, Fagan, Giulio, Flude, Ben Matthew, Bevilacqua, Federica, Santos-Ferreira, Nanci, Van Dycke, Jana, Neyts, Johan, Brancale, Andrea, Rocha-Pereira, Joana, Bassetto, Marcella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468020/
https://www.ncbi.nlm.nih.gov/pubmed/34576691
http://dx.doi.org/10.3390/microorganisms9091795
_version_ 1784573553312530432
author Ferla, Salvatore
Varricchio, Carmine
Knight, William
Ho, Pui Kei
Saporito, Fabiana
Tropea, Beatrice
Fagan, Giulio
Flude, Ben Matthew
Bevilacqua, Federica
Santos-Ferreira, Nanci
Van Dycke, Jana
Neyts, Johan
Brancale, Andrea
Rocha-Pereira, Joana
Bassetto, Marcella
author_facet Ferla, Salvatore
Varricchio, Carmine
Knight, William
Ho, Pui Kei
Saporito, Fabiana
Tropea, Beatrice
Fagan, Giulio
Flude, Ben Matthew
Bevilacqua, Federica
Santos-Ferreira, Nanci
Van Dycke, Jana
Neyts, Johan
Brancale, Andrea
Rocha-Pereira, Joana
Bassetto, Marcella
author_sort Ferla, Salvatore
collection PubMed
description Human norovirus is the leading cause of acute gastroenteritis worldwide, affecting every year 685 million people. Norovirus outbreaks are associated with very significant economic losses, with an estimated societal cost of 60 billion USD per year. Despite this, no therapeutic options or vaccines are currently available to treat or prevent this infection. An antiviral therapy that can be used as treatment and as a prophylactic measure in the case of outbreaks is urgently needed. We previously described the computer-aided design and synthesis of novel small-molecule agents able to inhibit the replication of human norovirus in cell-based systems. These compounds are non-nucleoside inhibitors of the viral polymerase and are characterized by a terminal para-substituted phenyl group connected to a central phenyl ring by an amide-thioamide linker, and a terminal thiophene ring. Here we describe new modifications of these scaffolds focused on exploring the role of the substituent at the para position of the terminal phenyl ring and on removing the thioamide portion of the amide-thioamide linker, to further explore structure-activity relationships (SARs) and improve antiviral properties. According to three to four-step synthetic routes, we prepared thirty novel compounds, which were then evaluated against the replication of both murine (MNV) and human (HuNoV) norovirus in cells. Derivatives in which the terminal phenyl group has been replaced by an unsubstituted benzoxazole or indole, and the thioamide component of the amide-thioamide linker has been removed, showed promising results in inhibiting HuNoV replication at low micromolar concentrations. Particularly, compound 28 was found to have an EC(50) against HuNoV of 0.9 µM. Although the most active novel derivatives were also associated with an increased cytotoxicity in the human cell line, these compounds represent a very promising starting point for the development of new analogues with reduced cytotoxicity and improved selectivity indexes. In addition, the experimental biological data have been used to create an initial 3D quantitative structure-activity relationship model, which could be used to guide the future design of novel potential anti-norovirus agents.
format Online
Article
Text
id pubmed-8468020
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84680202021-09-27 Structure–Activity Relationship Studies on Novel Antiviral Agents for Norovirus Infections Ferla, Salvatore Varricchio, Carmine Knight, William Ho, Pui Kei Saporito, Fabiana Tropea, Beatrice Fagan, Giulio Flude, Ben Matthew Bevilacqua, Federica Santos-Ferreira, Nanci Van Dycke, Jana Neyts, Johan Brancale, Andrea Rocha-Pereira, Joana Bassetto, Marcella Microorganisms Article Human norovirus is the leading cause of acute gastroenteritis worldwide, affecting every year 685 million people. Norovirus outbreaks are associated with very significant economic losses, with an estimated societal cost of 60 billion USD per year. Despite this, no therapeutic options or vaccines are currently available to treat or prevent this infection. An antiviral therapy that can be used as treatment and as a prophylactic measure in the case of outbreaks is urgently needed. We previously described the computer-aided design and synthesis of novel small-molecule agents able to inhibit the replication of human norovirus in cell-based systems. These compounds are non-nucleoside inhibitors of the viral polymerase and are characterized by a terminal para-substituted phenyl group connected to a central phenyl ring by an amide-thioamide linker, and a terminal thiophene ring. Here we describe new modifications of these scaffolds focused on exploring the role of the substituent at the para position of the terminal phenyl ring and on removing the thioamide portion of the amide-thioamide linker, to further explore structure-activity relationships (SARs) and improve antiviral properties. According to three to four-step synthetic routes, we prepared thirty novel compounds, which were then evaluated against the replication of both murine (MNV) and human (HuNoV) norovirus in cells. Derivatives in which the terminal phenyl group has been replaced by an unsubstituted benzoxazole or indole, and the thioamide component of the amide-thioamide linker has been removed, showed promising results in inhibiting HuNoV replication at low micromolar concentrations. Particularly, compound 28 was found to have an EC(50) against HuNoV of 0.9 µM. Although the most active novel derivatives were also associated with an increased cytotoxicity in the human cell line, these compounds represent a very promising starting point for the development of new analogues with reduced cytotoxicity and improved selectivity indexes. In addition, the experimental biological data have been used to create an initial 3D quantitative structure-activity relationship model, which could be used to guide the future design of novel potential anti-norovirus agents. MDPI 2021-08-24 /pmc/articles/PMC8468020/ /pubmed/34576691 http://dx.doi.org/10.3390/microorganisms9091795 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ferla, Salvatore
Varricchio, Carmine
Knight, William
Ho, Pui Kei
Saporito, Fabiana
Tropea, Beatrice
Fagan, Giulio
Flude, Ben Matthew
Bevilacqua, Federica
Santos-Ferreira, Nanci
Van Dycke, Jana
Neyts, Johan
Brancale, Andrea
Rocha-Pereira, Joana
Bassetto, Marcella
Structure–Activity Relationship Studies on Novel Antiviral Agents for Norovirus Infections
title Structure–Activity Relationship Studies on Novel Antiviral Agents for Norovirus Infections
title_full Structure–Activity Relationship Studies on Novel Antiviral Agents for Norovirus Infections
title_fullStr Structure–Activity Relationship Studies on Novel Antiviral Agents for Norovirus Infections
title_full_unstemmed Structure–Activity Relationship Studies on Novel Antiviral Agents for Norovirus Infections
title_short Structure–Activity Relationship Studies on Novel Antiviral Agents for Norovirus Infections
title_sort structure–activity relationship studies on novel antiviral agents for norovirus infections
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468020/
https://www.ncbi.nlm.nih.gov/pubmed/34576691
http://dx.doi.org/10.3390/microorganisms9091795
work_keys_str_mv AT ferlasalvatore structureactivityrelationshipstudiesonnovelantiviralagentsfornorovirusinfections
AT varricchiocarmine structureactivityrelationshipstudiesonnovelantiviralagentsfornorovirusinfections
AT knightwilliam structureactivityrelationshipstudiesonnovelantiviralagentsfornorovirusinfections
AT hopuikei structureactivityrelationshipstudiesonnovelantiviralagentsfornorovirusinfections
AT saporitofabiana structureactivityrelationshipstudiesonnovelantiviralagentsfornorovirusinfections
AT tropeabeatrice structureactivityrelationshipstudiesonnovelantiviralagentsfornorovirusinfections
AT fagangiulio structureactivityrelationshipstudiesonnovelantiviralagentsfornorovirusinfections
AT fludebenmatthew structureactivityrelationshipstudiesonnovelantiviralagentsfornorovirusinfections
AT bevilacquafederica structureactivityrelationshipstudiesonnovelantiviralagentsfornorovirusinfections
AT santosferreirananci structureactivityrelationshipstudiesonnovelantiviralagentsfornorovirusinfections
AT vandyckejana structureactivityrelationshipstudiesonnovelantiviralagentsfornorovirusinfections
AT neytsjohan structureactivityrelationshipstudiesonnovelantiviralagentsfornorovirusinfections
AT brancaleandrea structureactivityrelationshipstudiesonnovelantiviralagentsfornorovirusinfections
AT rochapereirajoana structureactivityrelationshipstudiesonnovelantiviralagentsfornorovirusinfections
AT bassettomarcella structureactivityrelationshipstudiesonnovelantiviralagentsfornorovirusinfections